Key Takeaways AMRX reaffirmed 2026 revenue guidance of $3.05B-$3.15B and raised EBITDA and EPS outlook.Affordable Medicines is expected to drive growth with 20-30 annual launches and biosimilars.Specialty faces Rytary erosion, while Crexont, Unithroid and Brekiya support results.Amneal Pharmaceuticals (AMRX) is leaning into a playbook that can work in multiple market backdrops. The company is pairing steady demand in generics with higher-value opportunities in complex injectables, biosimilars, and branded S ...